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a  b  s  t  r  a  c  t
INTRODUCTION:  Fungal  periprosthetic  joint  infection  (PJI)  is  a disruptive  and  complex  complication  of
joint  arthroplasty.  We  present  a case  of a fungal  PJI with  Candida  parapsilosis  after  a total  hip  arthroplasty
(THA).
PRESENTATION  OF  CASE:  A  73-year-old  woman  with  a history  of ovarian  cancer  with  peritoneal  metas-
tases, was  treated  with  a  THA, due  to symptomatic  arthritis  of the right  hip. One  month  after  surgery,  she
had difficulties  walking.  Inflammatory  parameters  were  mildly  increased.  Aspiration  of  a  subcutaneous
abscess  diagnosed  Candida  parapsilosis.  A  two-stage  revision  arthroplasty  without  spacer  was  performed.
During  a six-week  prosthesis-free  interval,  intravenous  fluconazole  400  mg  was  given.  After  reimplan-
tation,  fluconazole  was  continued  for two  weeks  intravenously  and life-long  perorally.  Follow-up  of  the
patient  after  six  months  showed  no recurrence  of infection.
DISCUSSION:  This  case  revealed  that  when  PJI  is suspected,  a low  treshold  for joint  aspiration  is  impor-
tant.  Two-stage  revision  with  systematic  antifungal  therapy  is  the  preferred  treatment  of  fungal  PJI.  Our
case  demonstrated  a good  result  with  a prosthesis-free  interval.  Fluconazole  is the preferred  antifungal
treatment  and it  should  be applied  for at least  six months  or  longer.
CONCLUSION:  To  our  knowledge,  this  is  the  first  case  of  a fungal  PJI  with Candida  parapsilosis  after  a THA
 revis
 Publi
 artictreated  with  a  two-stage
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. Introduction
Periprosthetic joint infection (PJI) is one of the most disrup-
ive and complex complications of joint arthroplasty [1]. The most
ommon pathogens associated with PJI are Staphylococcus species,
hich are seen in 50–60% of all cases [1].
Fungal infection at the site of the joint replacement is rare and
s estimated to appear in approximately 1% of all PJIs [2]. As they
an lead to destructive consequences if not treated timely, fungal
JI is a diagnostic and therapeutic challenge [1,2].
We present a case of Candida parapsilosis early PJI in a total hip
rthroplasty (THA) of a 73-year-old woman. A two-stage revision
rthroplasty without spacer was performed.
Abbreviations: PJI, periprosthetic joint infection; CRP, c-reactive protein; ESR,
rythrocyte sedimentation rate; DTT, difficult-to-treat; TKA, total knee arthroplasty;
HA, total hip arthroplasty; HPF, high power field; MSIS, Muskuloskeletal Infection
ociety; EBJIS, European Bone and Joint Infection Society; IDSA, Infectious Diseases
ociety of America; DAIR, Debridement, antibiotics, irrigation and retention.
∗ Corresponding author at: Department of Orthopaedic Surgery and Traumatol-
gy, General Hospital St-Lucas, Groenebriel 1, Ghent, Belgium.
E-mail address: laurence.vergison@skynet.be (L. Vergison).
ttps://doi.org/10.1016/j.ijscr.2020.03.037
210-2612/© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group
rg/licenses/by/4.0/).ion  arthroplasty  without  spacer  and  a  life-long  fluconazole  treatment.
shed  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
le under  the  CC  BY license  (http://creativecommons.org/licenses/by/4.0/).
Furthermore, a clear description of the current literature on the
risk factors, clinical features and therapeutic strategies of fungal PJI
is presented. The work has been reported in line with the SCARE
criteria [3].
2. Presentation of case
A 73-year-old woman, treated for ovarian cancer with peri-
toneal metastases, was  known with symptomatic arthritis of the
right hip. She was treated conservatively with intra-articular infil-
trations, because of active treatment of the peritoneal disease
with Bevacizumab (Avastin®), a monoclonal antibody that pre-
vents wound healing. Due to the heavy impact of the hip arthritis
on her quality of life, the patient asked for an operative solution,
more specifically a THA. In consultation with the oncologist, Beva-
cizumab was temporarily interrupted. Four months after the third
intra-articular infiltration, she was  treated with a THA. The THA was
performed through a direct anterior approach. A cementless tita-
nium porous coated cup and a cementless titanium straight stem
with polyethylene liner and a ceramic femoral head were used.
Exactly one month after surgery, she was not able to walk with-
out pain in her right hip, after she was  painfree the first two  weeks.
A positive Trendelenburg was present. Hip range of motion (ROM)
 Ltd. This is an open access article under the CC BY license (http://creativecommons.
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Fig. 2. Plain X-ray after removal of the total hip arthroplasty. A prosthesis-free
interval of 6 weeks was performed.
As other microorganisms such as rifampin-resistant staphy-Fig. 1. Plain X-ray shows no arguments of prosthetic loosening.
as slightly reduced in intern rotation. There was  no skin ery-
hema or signs of sinus tract. She was afebrile (T: 36,3 C) and had
o malaise. The radiographs showed no arguments of prosthetic
oosening (Fig. 1). The C reactive protein (CRP) and erythrocyte
edimentation rate (ESR) were mildly increased, up to 67 mg/L (ref-
rence value: < 5 mg/L) and 36 mm/h  (reference value: 2–15 mm/h)
espectively.
A percutaneous aspiration of the right hip was performed, two
ays after the blood results. Due to an insufficient amount of fluid,
 second aspiration by ultrasound was done. The ultrasound scan
howed an extended subcutaneous abscess of 80 mm long and
0 mm deep. Both cultures revealed Candida parapsilosis.
At day 40, the prosthesis was removed and the surrounding tis-
ues were debrided (Fig. 2). A two-stage exchange without spacer
nd with a long interval was chosen. A six-week course of intra-
enous fluconazole at 400 mg  daily was started. Six weeks after
he removal of her initial prosthesis, a revision THA was performed
hrough a postero-lateral approach. A cementless dual mobility cup
nd a cemented titanium straight stem with polyethylene liner
nd a ceramic femoral head were used (Fig. 3). After reimplan-
ion of the hip prosthesis, the antifungal therapy was continued
or two weeks intravenously and life-long perorally. Follow-up of
he patient after six months showed no recurrence of infection and
 painfree mobilisation of the right hip.
. Discussion
.1. Pathogenesis
Fungal infection after total joint replacement is rare and is seen
n approximately 1% of all PJIs [2]. The majority of these infections
re caused by Candida (albicans, parapsilosis, glabrata, tropicalis),
spergillus, Coccidioides and Blastomycetes [2].
Over the past two decades, the Candida parapsilosis pathogen
s on the rise worldwide. C. parapsilosis is known to be a nor-
al  human commensal, considering the fact that it is one of the
ost commonly isolated fungi from the subungal space of human
ands. In contrast to C. albicans and C. tropicalis, prior colonization
s not obligate present in infections caused by C. parapsilosis, as it is
sually transmitted horizontally through human hands, prosthetic
evices, medical fluids and catheters [4].Fig. 3. Plain X-ray after revision of the total hip arthroplasty with dual mobility cup
and  cemented stem.
The increase of C. parapsilosis and other fungal PJI has been
attributed to a higher risk in immunosuppressed patients, induced
by underlying causes including malignant diseases, drug therapies,
antibiotic overuse, indwelling catheters, diabetes, tuberculosis,
multiple revision surgery and intravenous drug use [4,5].
Some of these risk factors were seen in our case, such as malig-
nant disease and the previous drug therapy with Bevacizumab,
which prevents wound healing.lococci, enterococci and ciprofloxacin-resistant gram-negative
bacteria, fungi are defined as difficult-to-treat (DTT) organisms.
These pathogens produce complex biofilms which provide resis-
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Table 1
Diagnostic criteria of PJI according to the EBJIS (2018). At least one the following 4 criteria must be fulfilled [9].
Diagnostic test Criteria Sensitivity Specificity
Clinical features Sinus tract or visible purulence around the prosthesis 20–30% 100%
Leukocytes in synovial fluid > 2000/l  leukocytes or ≥70% granulocytes 93–96% 93–96%
Histology Inflammation in periprosthetic tissue (>2 granulocytes/HPF) 95–98% 95–98%
Microbiology (culture)
Synovial fluid or 60–80% 97%












































Sonication fluid (≥50 CFU/mL) 
a For highly virulent organisms (e.g. Staphylococcus aureus, Escherichia coli) one p
ance to biofilm-active antimicrobials by limiting the penetration
f substances through the matrix [6].
.2. Clinical features
Patients infected by fungal organisms do not mandatorily show
he same symptoms as those infected by bacterial organisms. The
ymptoms are often indolent and can variate between pain, ery-
hema, swelling, and decreased mobility. Systemic signs, such as
ever, chills or malaise are relatively uncommon [7]. A thorough
valuation of the previous incisions is necessary. The mean interval
etween initial surgery and clinical signs is 21 months [6].
.3. Diagnosis
An early diagnosis of PJI is of major importance for preserving
he prosthesis and the joint functionality. Criteria for diagnosis of PJI
ere described by the Muskuloskeletal Infection Society (MSIS), the
uropean Bone and Joint Infection Society (EBJIS) and the Infectious
iseases Society of America (IDSA). Trampuz et al. described the
BJIS criteria as the most sensitive criteria for PJI (Table 1) [8,9].
The diagnosis of a fungal PJI can be rather challenging. In contrast
o bacterial PJI, routine inflammatory parameters are not necessar-
ly elevated in fungal PJI [5]. Another difficulty in the diagnosis is
he misinterpretation of positive fungal culture as contaminant. A
ungal organism in tissue or fluid sample obtained by aspiration
f a prosthetic joint can be seen as a genuine infection or fungal
olonization. Several authors emphasize the importance of multi-
le positive tissue cultures before the diagnosis of fungal PJI can be
ade [5]. However, according to other authors, one positive sample
ay  confirm the diagnosis of PJI in case of highly virulent organisms
8,9].
.4. Treatment
Several treatment options for PJI have been described, includ-
ng debridement with polyexchange, one- or two-stage revision
rthroplasty and chronic suppressive therapy [2].
Debridement, antibiotics, irrigation and retention (DAIR) is not
ecommended as treatment for fungal PJI. Due to the complex
iofilm formation, debridement alone will leave fungal remnants
t the site of the infection [5].
A two-stage revision is the preferred treatment for fungal PJI.
ntifungal treatment should be applied between explantation and
eimplantation for at least 6 weeks, as described by the IDSA
11]. Fluconazole is the preferred antifungal treatment for fungal
JI. Amphotericin B lipid formulations or echinocandins are other
ptions but may  be less tolerated due to the side effects. Revision
hould be performed when there are no clinical signs of infection
nd blood infection markers have normalized. Following reimpla-
ation, daily treatment with fluconazole 400 mg  (6 mg/kg) should
e maintained for 6 months or longer, if tolerated [10]. Some reports
uggest a two-week antimicrobial holiday prior to reimplantation,
n order to collect true tissue specimens for culture at the time85–95% 95%
e tissue sample is sufficient to confirm infection.
of reimplantation [6]. However, there is no conclusive evidence to
support the antimicrobial holiday period [10].
Kuiper et al. analyzed 164 patients who had fungal PJI after
TKA and THA and described a success rate of 67/79 (85%) in those
patients who underwent a two-stage revision in a follow-up period
of more than two  years [11]. Other authors reported eradication
rates of 41% and 50% after two-stage revision [1,12].
Zimmerli et al. proposed a two-stage exchange without a spacer
as a suitable treatment for difficult-to-treat microorganisms [6]. A
temporary antifungal-impregnated spacer has multiple advantages
such as preservation of the joint space, a high local concentration of
antifungal drugs and an easier reimplantation due to the absence
of scar tissue in the medullary canal and in the acetabulum. How-
ever, as spacers may  be seen as a foreign body, microorganisms may
adhere and continue the infection. Furthermore, various mechani-
cal complications when using cement spacers have been reported
such as spacer fractures, dislocations and femoral fractures [13].
Antifungal treatment without surgery is not suggested and
should only be supported if the patient refuses surgery or the sur-
gical procedure is associated with high risk of the patient’s life [8].
In this case, chronic suppressive therapy after reimplantation has
been chosen to prevent relapse.
4. Conclusion
Fungal PJI is a diagnostic and therapeutic challenge as it can lead
to destructive consequences [7]. We emphasize the importance of
a low threshold for joint aspiration when PJI is suspected.
Two-stage revision with systematic antifungal therapy is the
preferred treatment of fungal PJI with eradication rates between
50% and 93% [12]. DAIR is not recommended as a treatment option
for fungal PJI, due to the complex biofilm formation of fungal
pathogens [5].
Our case demonstrated an early recognition and treatment of
a fungal PJI after THA. A two-stage revision without spacer was
used in combination with 6 weeks of fluconazole intravenous dur-
ing the prosthesis-free interval. After reimplantation, fluconazole
was continued for two  weeks intravenously and life-long perorally.
A consensus for this challenging problem is lacking due to inho-
mogeneous study cohorts, a limited number of case reports and
case series and the small patient numbers. Both the duration of the
antifungal therapy after reimplantation as two-stage revision with
or without spacer remain questionable. Future high-quality studies
are necessary to accurately manage fungal PJI.
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